Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

783
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
783
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

723
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
723
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

277
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
277
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

824
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
824
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

227
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
227

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exercise Capacity, Endothelial Function, Muscle Mass, and Strength in Pediatric Patients With Fontan Circulation.

CJC pediatric and congenital heart disease·2026
Same author

The impact of climate change on psychiatric decompensation: A case report using the climate biopsychosocial framework.

The journal of climate change and health·2026
Same author

Beta-Adrenergic Stimulation and <i>MYH7</i> G256E Mutant Gene Dosage Drive Hypertrophic Cardiomyopathy Phenotype Penetrance.

bioRxiv : the preprint server for biology·2026
Same author

Python metabolomics uncovers a conserved postprandial metabolite and gut-brain feeding pathway.

Nature metabolism·2026
Same author

Cryo-ET reveals nanoscale thick filament disorganization in MYH7 P710R hypertrophic cardiomyopathy cardiomyocytes.

bioRxiv : the preprint server for biology·2026
Same author

Python metabolomics uncovers a conserved postprandial metabolite and gut-brain feeding pathway.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jan 21, 2026

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.4K

Stem cells: will they cure pediatric heart failure?

Daniel Bernstein1

  • 1Department of Pediatrics (Cardiology), Stanford Cardiovascular Institute, Stanford University, Stanford, California, USA.

Current Opinion in Pediatrics
|July 24, 2019
PubMed
Summary

Cardiac regenerative medicine shows promise for children, but clinical trials lack convincing evidence of effectiveness. More research is needed to overcome challenges before successful translation in pediatric patients.

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

Related Experiment Videos

Last Updated: Jan 21, 2026

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.4K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

Area of Science:

  • Cardiovascular Research
  • Regenerative Medicine
  • Pediatric Cardiology

Background:

  • Stem cell therapies for heart failure in adults have proliferated but yielded limited clinical benefits.
  • Understanding the limitations of current stem cell treatments is crucial for clinical translation.
  • Pediatric cardiac regeneration presents unique opportunities due to younger hearts' repair potential and less scar tissue.

Purpose of the Study:

  • To review the current status of cardiac regenerative medicine.
  • To highlight opportunities and challenges in applying these therapies to pediatric patients.

Main Methods:

  • Review of existing clinical studies and animal models in cardiac regeneration.
  • Analysis of the potential and limitations of stem cell therapies in pediatric cardiac disease.

Main Results:

  • Rapid advancement in clinical trials for cardiac regeneration, particularly using stem cells.
  • Lack of convincing evidence for clinically significant improvement in both adult and pediatric patients.
  • Potential for greater regenerative capacity in children compared to adults.

Conclusions:

  • Significant biological mechanisms in cardiac regeneration remain to be elucidated.
  • Future pediatric clinical trials must be grounded in robust animal model evidence for safety and efficacy.
  • Rigorous, controlled studies are essential to validate stem cell therapies in pediatric cardiac regeneration.